{
    "nctId": "NCT05412459",
    "briefTitle": "99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy",
    "officialTitle": "SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Using 99mTc-DARPinG3 in HER2-positive Breast Cancer Patients in Dynamic of Chemo+Targeted Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "HER2-positive Breast Cancer, Female",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "SPECT/CT-based 99mTc-DARPinG3 uptake value in primary tumor (standardized uptake value (SUV))",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Subject is \\> 18 years of age;\n2. Diagnosis of primary breast cancer with tumour size \u2265 20 mm and with possible lymph node metastases;\n3. Availability of results from HER2 status previously determined on material from the primary tumor: HER2-positive, defined as a DAKO HercepTest\u2122 score of 3+ or FISH positive;\n4. In neoadjuvant all patients should receive standard chemo-targeted therapy according to the DCH+P (docetaxel + carboplatin+ trastuzumab+ pertuzumab) scheme;\n5. Injection of 99mTc-DARPinG3 at the dosage 3000 \u00b5g before and after 2 and 4 courses of chemo+targeted therapy in each HER2-positive breast cancer patient;\n6. Biopsies should be performed in all patients HER2-positive breast cancer patients before and after 2 and 4 courses of chemo+targeted therapy with evaluation of HER2 expression;\n7. Hematological, liver and renal function test results within the following limits:\n\n   * White blood cell count: \\> 2.0 x 109/L\n   * Hemoglobin: \\> 80 g/L\n   * Platelets: \\> 50.0 x 109/L\n   * ALT, ALP, AST: =\\< 5.0 times Upper Limit of Normal\n   * Bilirubin =\\< 2.0 times Upper Limit of Normal\n   * Serum creatinine: Within Normal Limits\n8. A negative pregnancy test for all patients of childbearing potential. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination;\n9. Subject is capable to undergo the diagnostic investigations to be performed in the study;\n10. Informed consent\n\nExclusion Criteria:\n\n1. Second, non-breast malignancy\n2. Active current autoimmune disease or history of autoimmune disease\n3. Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening) 4. Known HIV positive or chronically active hepatitis B or C\n4. Administration of other investigational medicinal product within 30 days of screening\n5. Ongoing toxicity \\> grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}